poisar

Stocks · News reference

AEON Biopharma shares are trading higher after the company announced that the FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX may be submitted as supportive evidence.

BenzingaBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading